Drug Search Results
Using advanced filters...
Advanced Search [+]

KFA-115

Alternative Names: KFA-115, KFA 115, KFA115, NVP-KFA115
Latest Update: 2025-03-05
Latest Update Note: Clinical Trial Update

Product Description

KFA-115, also known as NVP-KFA115, is an immunomodulatory agent being developed by Novartis for the treatment of select advanced cancers. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05544929?term=KFA-115&draw=2&rank=1)

Mechanisms of Action: Immunomodulator

Novel Mechanism: No

Modality: N/A

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KFA-115

Countries in Clinic: Canada, China, France, Germany, Hong Kong, Italy, Japan, Korea, Singapore, Spain, Taiwan, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 1: Anus Cancer|Colorectal Cancer|Cutaneous Squamous Cell Carcinoma|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Melanoma|Mesothelioma|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Thymoma|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CKFA115A12101

P1

Recruiting

Colorectal Cancer|Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer|Gastrointestinal Cancer|Esophageal Cancer|Cutaneous Squamous Cell Carcinoma|Renal Cell Carcinoma|Melanoma|Anus Cancer|Mesothelioma|Head and Neck Cancer|Squamous Cell Carcinoma|Thymoma|Ovarian Cancer|Nasopharyngeal Cancer

2027-09-01

4%

jRCT2031230410

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

2025-12-31

CTR20250770

P1

Recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title